SpringWorks Therapeutics Future Growth
Future criteria checks 2/6
SpringWorks Therapeutics is forecast to grow earnings and revenue by 44.7% and 45.4% per annum respectively while EPS is expected to grow by 44.4% per annum.
Key information
44.7%
Earnings growth rate
44.4%
EPS growth rate
Biotechs earnings growth | 24.4% |
Revenue growth rate | 45.4% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 06 May 2024 |
Recent future growth updates
Recent updates
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15SpringWorks shows durable effect for neurofibroma therapy with long-term data
Jun 15SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma
Jun 07We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow
May 31SpringWorks Therapeutics EPS misses by $0.11
May 06SpringWorks Therapeutics announces C-level promotions
Dec 15SpringWorks Therapeutics EPS misses by $0.02
Nov 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 639 | -70 | N/A | N/A | 2 |
12/31/2025 | 289 | -270 | -201 | -200 | 7 |
12/31/2024 | 135 | -348 | -259 | -257 | 6 |
3/31/2024 | 26 | -339 | -245 | -240 | N/A |
12/31/2023 | 5 | -325 | -230 | -223 | N/A |
9/30/2023 | N/A | -305 | -226 | -214 | N/A |
6/30/2023 | N/A | -298 | -195 | -183 | N/A |
3/31/2023 | N/A | -289 | -185 | -175 | N/A |
12/31/2022 | N/A | -277 | -172 | -162 | N/A |
9/30/2022 | N/A | -259 | -164 | -154 | N/A |
6/30/2022 | N/A | -228 | -168 | -161 | N/A |
3/31/2022 | N/A | -206 | -160 | -155 | N/A |
12/31/2021 | N/A | -174 | -130 | -128 | N/A |
9/30/2021 | 35 | -107 | -67 | -66 | N/A |
6/30/2021 | 35 | -87 | -55 | -54 | N/A |
3/31/2021 | 35 | -60 | -37 | -37 | N/A |
12/31/2020 | 35 | -46 | -33 | -32 | N/A |
9/30/2020 | N/A | -73 | -64 | -63 | N/A |
6/30/2020 | N/A | -68 | -60 | -60 | N/A |
3/31/2020 | N/A | -62 | -57 | -57 | N/A |
12/31/2019 | N/A | -51 | -48 | -47 | N/A |
9/30/2019 | N/A | -41 | -35 | -34 | N/A |
6/30/2019 | N/A | -29 | -31 | -30 | N/A |
3/31/2019 | N/A | -18 | -20 | -19 | N/A |
12/31/2018 | N/A | -18 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SWTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SWTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SWTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SWTX's revenue (45.4% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: SWTX's revenue (45.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SWTX's Return on Equity is forecast to be high in 3 years time